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Abstract
The substantial progress in our understanding of molecular and cellular biology has allowed
us to design biological therapeutics (‘biologicals’) with defined targets and effector functions.
These biologicals have greatly contributed to our current knowledge of pathogenetic
mechanisms in autoimmune diseases. However, although some of the biologicals have been
extremely successful in treating the symptoms of chronic inflammation, biological therapy has
not yet met the expectations of permanently silencing the chonic immune response. In this
commentary we discuss current concepts and future directions of biological therapy, and the
potential usefulness of biologicals as a treatment of human autoimmune diseases in
appropriate critical applications with the use of suitably designed agents.
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Biological therapy refers to treatment strategies of human
diseases employing compounds as therapeutic modalities
that have been generated by living cells, in contrast to
conventional pharmacologicals which are generally syn-
thesized chemically. The substantial progress in our
understanding of molecular and cellular biology in recent
years has allowed us to use different cellular sources for
the production of a variety of potential biological therapeu-
tics (‘biologicals’) such as monoclonal antibodies (mAbs)
and recombinant cytokines in highest qualities and sub-
stantial quantities. Furthermore, genetic engineering has
opened the road to the specific modification of existing
proteins and thus the design of new ones, for example by
engrafting the complementarity-determining regions of
murine mAbs on the variable regions of a human
immunoglobulin or by creating fusion proteins between
receptor molecules and immunoglobulins.
The use of biological therapy in human autoimmune dis-
eases is motivated by the desire to interfere specifically
with pathogenetic mechanisms of the respective diseases
and thereby modulate the course of, and ultimately stop,
the chronic inflammatory processes without imposing
unbearable toxicity. Because autoimmune diseases result
from specific immune responses against self-antigens,
immunosuppressive drugs have long been employed withArthritis Research    Vol 2 No 5 Schulze-Koops and Kalden
some clinical benefit. However, because they are associ-
ated with a number of side effects related to general
immunosuppression, they cannot be considered optimal
therapy. An ideal form of therapy would be one that exclu-
sively targeted those cells perpetuating the chronic inflam-
mation with minimal effects on other aspects of the
immune or inflammatory systems. Although the present
understanding of the pathogenesis of human autoimmune
diseases is still incomplete, it has become clear in recent
years that the mechanisms resulting in the destruction of
tissue and the loss of organ function during the course of
an autoimmune disease are essentially the same as those
in protective immunity against invasive microorganisms.
Of fundamental importance in initiating, controlling and
driving these specific immune responses are CD4+ T cells.
CD4+ T cells are activated by an antigen (a peptide) recog-
nized specifically by their T cell receptor if presented in the
context of a specific MHC (major histocompatibility
complex) class II molecule on the surface of an antigen-
presenting cell. Once activated, CD4+ T cells become the
central regulators of specific immune responses and deter-
mine to a large extent the outcome of immune reactions by
activating different effector functions of the immune
system. It is therefore no surprise that activated CD4+
T cells can be found in inflammatory infiltrates in many
human autoimmune diseases and it is generally agreed that
CD4+ T cells have a pivotal role in initiating and maintaining
autoimmunity. The induction of tissue-damaging autoimmu-
nity in some animal models of autoimmune diseases by the
transfer of CD4+ T cells from sick animals into healthy syn-
geneic recipients can be regarded as further evidence of
the importance of CD4+ T cells in autoimmunity.
Consequently, on the basis of the concept that activated
CD4+ T cells are the key mediators of chronic autoimmune
inflammation, patients with autoimmune diseases have
been given biologicals that interfere with the activation of
T cells, and in particular CD4+ T cells, such as mAbs
against CD4, CD5, CD7, CD25 and CD52. The data from
those trials have been reported in detail [1–3], and an
extensive review of the clinical experience is beyond the
scope of this commentary. It became apparent from those
initial studies that biologicals can safely be given to
patients with relatively few and minor side effects and that
the application of mAbs to T cell surface receptors might
be associated with a clinical benefit. However, those
studies have also raised several issues that will need to be
addressed before mAb therapy to T cell surface receptors
can be considered for wider use as a treatment principle.
First, so far neither the specific autoantigen(s) eliciting
human autoimmune diseases nor the specific disease initi-
ating or perpetuating T cells are known. Thus, as outlined
above, targeting activated T cells or T cell subsets is so far
the most rational approach to combating T cell-mediated
autoimmunity in humans feasible. However, this approach
does not meet the expectations of exclusively affecting
only those cells involved in the pathogenesis of the
disease. Therefore, although they were not seen in the
initial trials, one still has to be observant for possible
unwanted side effects of a sustained depression of T cell
function by the prolonged application of T cell-directed
biologicals, for example increased prevalences of oppor-
tunistic infections and/or malignancies.
Second, with very few exceptions, the mAbs employed
have generally failed to induce a sustained clinical
improvement. In animals, mAbs against CD4 have been
used successfully not only to prevent the induction of the
disease in a variety of experimental autoimmune diseases
but also to inhibit further disease progression when given
after the initial inflammation has already become manifest
[4–6]. However, the hope that mAbs might ‘reprogram’
the immune response in humans and permanently silence
those CD4+ T cells that were activated, for example, under
the ‘umbrella’ of an anti-CD4 mAb [7,8] has so far been
completely unfulfilled.
Third, controlled clinical studies have largely failed to
confirm the initial encouraging clinical observations
(reviewed in [1–3]). A number of reasons, such as differ-
ences in study design, the use of diverse biological agents
directed against the same target molecule with unexpected
variances in biological activity and different definitions of a
clinical response, might have contributed to the unfavorable
results of the placebo-controlled trials. Moreover, in animal
studies it has been demonstrated that, for example, concen-
trations of an anti-CD4 mAb above a specific threshold
were necessary for anti-CD4 mAb-induced tolerance which,
in addition, takes many weeks of treatment to become com-
plete. However, those requirements were rarely met by the
human studies. One notable exception to the disappointing
controlled clinical trials was a study in which a non-deplet-
ing mAb against CD4, OKTcdr4a, was employed in patients
with severe refractory rheumatoid arthritis (RA) [9]. The
results from this placebo-controlled double-blind multicenter
study suggest that clinical improvement in patients with
refractory RA can be achieved by a non-depleting mAb
against CD4. Repeated administration of the anti-CD4 mAb
resulted in increased clinical benefit. Most interestingly, a
profound impact on T cell functions was induced by the
mAb, leading to a marked diminution in the capacity of
peripheral blood mononuclear cells to produce pro-inflam-
matory cytokines [9]. Carefully designed future studies that
take the concerns and arguments outlined above into con-
sideration will have to show whether biologicals directed
against T cell receptors are not only safe, but also powerful
immunomodulatory agents capable of permanently terminat-
ing unwanted and pathogenic autoimmune reactivity, if
employed under appropriate critical conditions with suitably
designed mAbs.http://arthritis-research.com/content/2/5/337
Because of the central role of T cells in initiating and per-
petuating the chronic immune reactions characteristic of
autoimmune diseases, it was natural to employ biologicals
first that directly interfered with T cell function by targeting
the T cells themselves. However, T cell effector functions
at sites of inflammation might also be regulated by control-
ling the recruitment of the lymphocytes into the tissue by
targeting adhesion receptors. Several lines of evidence
suggest that interactions between the endothelial cells of
post-capillary venules and mononuclear cells in the circu-
lation, mediated by a variety of adhesion molecules,
govern the entry of inflammatory cells into the tissues [10].
Thus, one possible target for adhesion receptor-directed
therapy is the adhesion receptor–counter-receptor pair
leukocyte-function-associated antigen-1 (LFA-1, CD11a/
CD18) and intercellular adhesion molecule-1 (ICAM-1,
CD54). The interaction of these receptors is critical for the
transendothelial migration of T cells and for their subse-
quent activation [11,12]. In one clinical study, the hypothe-
sis was tested that the application of a mAb against
ICAM-1 was able to ameliorate the signs and symptoms of
RA by blocking the migration of T cells into the synovium
and their subsequent stimulation by locally expressed anti-
genic peptides in vivo [13]. Although the study was not
especially designed to test clinical efficacy, the data are
consistent with the conclusion that ICAM-1 has a central
role in rheumatoid inflammation and might therefore be an
important target in the treatment of RA. With our increasing
knowledge of the adhesion receptors involved in control-
ling the transendothelial migration of T cells and, more
specifically, T cell subsets, treatment principles targeting
adhesion receptors, including chemokine receptors, should
be of major interest for study in the future. However,
because the mAb against ICAM-1 was of murine origin, it
was of considerable immunogenicity. When patients were
treated again with this agent, immune-complex-mediated
side effects, including urticaria, angioedema, and serum
complement protein consumption, were noted [14]. There-
fore, if this type of treatment is to be of any beneficial effect
in autoimmune diseases, it has to be substantiated with
further trials in double-blind placebo-controlled studies with
agents of lower immunogenicity.
Whereas the cellular basis of the immunopathogenesis of
human autoimmune diseases has not been completely
resolved, it has become clear that the excessive produc-
tion of cytokines contributes to the pathogenesis of most
of the diseases [15,16]. For example, many pro-inflamma-
tory cytokines, in particular tumor necrosis factor (TNF)-a
and IL-1, were demonstrated to be present in inflamed
rheumatoid joints in high concentrations and also to be
expressed in high copy numbers in synovial tissue, where
they seem to account for many of the pathological and
clinical manifestations of the disease [15]. TNF-a and IL-1
both contribute to leukocyte migration into the inflamed
tissue by activating endothelial cells, and, probably more
importantly, promote cartilage and bone resorption and
destruction by suppressing the synthesis of matrix compo-
nents and by the stimulation of metalloproteinase produc-
tion in fibroblasts [17]. Thus, the idea of blocking the
biological activity of TNF-a or IL-1 became an attractive
treatment principle. Neutralization of these cytokines can
be achieved by a variety of different methods such as
mAbs directed against the cytokines themselves, by mAbs
blocking the interaction of the cytokines with their recep-
tor, by applying cytokine receptor antagonists that bind to
the cytokine receptors without expressing an intrinsic
activity on the target cells, or by soluble cytokine recep-
tors. During the past decade, all of those reagents have
been explored as therapeutic means for treating autoim-
mune diseases. Some of the cytokine-directed biologicals
have entered the clinic, where they have contributed sub-
stantially to the immense progress that has been made in
recent years in the management of patients with autoim-
mune diseases. Currently, biologicals that neutralize TNF-
a have established themselves as a most valuable
treatment alternative for an increasing number of auto-
immune diseases.
The clinical efficacy of neutralizing TNF-a as demonstrated
in the various trials seems to be obvious [18–22];
however, the optimal treatment regimens with respect to
dosage and duration and interval of application still need
to be defined. Moreover, it should be kept in mind that in
applying anti-inflammatory cytokines or pro-inflammatory
cytokine inhibitors one has to be aware of our lack of
knowledge of side effects that might appear during a
longer course of treatment. For example, 7% of RA
patients who were treated with one mAb against TNF-a
developed antibodies against nuclei and against double-
stranded DNA of the IgM and IgG subclasses [23].
Although these antibodies disappeared with the cessation
of therapy, possible long-term effects of these autoanti-
bodies have not been documented. Finally, it has not been
shown in greater detail whether long-term neutralization of
TNF-a might be associated with the induction of any form
of malignancy.
The success of the biologicals, in particular their clinical
efficacy combined with their currently documented high
degree of safety, has shown that a complex disease such
as RA can be safely modulated by new therapeutic strate-
gies that are directed to modulate a specific aspect of the
underlying autoimmune process, thus avoiding general
immunosuppression. However, it is becoming clear that
decreasing the degree of global immunosuppression
associated with therapy by employing targeted specificity
might decrease the likelihood that a single therapeutic
agent will provide long-term disease control. Conse-
quently, biologicals are currently combined with conven-
tional anti-rheumatic drugs in an attempt to achieve asynergistic clinical efficacy without increased toxicity. For
example, the combination of methotrexate with TNF-a
inhibitors has already provided some encouraging results
[24]. In animal models, a synergy of combination biological
therapy has also been demonstrated and it is to be
expected that many of those combinations will also be
tested clinically. Pilot studies of a combination treatment
with mAbs against CD4 and against TNF-a are already
under way and the simultaneous use of TNF-a and IL-1
inhibitors will also be tested shortly.
Apart from the treatment principles described here in more
detail, other innovative therapeutic strategies have been
defined, some of which have already entered clinical trials.
It will be interesting to observe the effect of those biologi-
cals, such as inhibitors of CD28-mediated T cell co-stimu-
lation, or recombinant cytokines that might modulate T cell
effector function (IL-4, IL-10). An exciting approach to the
treatment of autoimmune diseases, based on the increas-
ing knowledge of different T helper (Th)-cell-mediated
effector functions, has been discussed recently [25]. As
evidence emerges that immune responses driven preferen-
tially by activated Th1 cells seem to have a central role in
the pathogenesis of several organ-specific autoimmune
diseases in animals [26–28], recent data suggest that RA
might reflect ongoing inflammation largely mediated by Th0
or Th1 cells without sufficient differentiation of Th2 cells to
downmodulate inflammation [29]. Thus, the idea of switch-
ing the apparently detrimental Th1-dominated chronic
immune response in RA into Th2-mediated immunity is
intriguing. This treatment principle has been applied suc-
cessfully to various animal models of human autoimmune
diseases [30]. However, clinical trials in humans have not
yet been conducted but will certainly be performed as soon
as appropriate biologicals become available. In this regard,
it is of interest to note that a defect in Th2 cell differentia-
tion is characteristic of early stages of RA [31]. As molecu-
lar mechanisms involved in directing Th1 or Th2 cell
differentiation are defined, they might serve as new targets
for therapeutic immunomodulation, by either inhibitory or
activatory biologicals, respectively.
Of all biologicals employed in the clinic so far, none has
been specific for the cells or mechanisms involved in the
pathogenesis of the respective diseases. Rather, although
the tools were generally more specific than conventional
immunosuppressants, they were still aimed at a broad
range of targets throughout the body. If the eliciting
autoantigen(s) of the diseases were known, one could
target explicitly those T cells mediating the inflammation. It
has been demonstrated that the replacement of single
amino acids in immunogenic peptides might alter the dif-
ferentiation of T cells to perform certain effector functions
[32]. Thus, altering the T cell receptor ligand with a
peptide analogue on functional antigen-presenting cells
might deliver a signal to a T cell that confers differentiation
of immunomodulatory rather than pro-inflammatory effector
cells (‘immune deviation’). In animal models, altered
peptide ligands have been used successfully to prevent
the onset and even inhibit the progress of experimental
autoimmune diseases [33]. It is to be expected that treat-
ment principles based on the concept of immune deviation
will be tested in the clinic in the future.
In conclusion, on the basis of our expanding knowledge of
the immune system, various biologicals have been
designed, produced and employed in the clinic over the
past decade. Although some biologicals have proved to
be extremely successful in treating the symptoms of
chronic inflammation and also seem to be able to slow
disease progression, biological therapy has not yet met
the expectations of permanently silencing chronic
(auto)immune inflammation. However, it can be expected
that an increasing understanding of the basic mechanism
of immunity will define new possible target structures for
therapeutic intervention. Therefore, exciting biological
tools will enter the clinic and be tested for their efficacy in
treating autoimmune diseases. It remains to be shown
whether they will be able to terminate unwanted and path-
ogenic autoimmune reactions. Nevertheless, with the
progress of recent years in mind, it is fair to keep our
expectations high.
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